CO6551670A2 - Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo - Google Patents
Métodos y sistemas para purificar la neurotoxina botulínica libre de complejoInfo
- Publication number
- CO6551670A2 CO6551670A2 CO12070154A CO12070154A CO6551670A2 CO 6551670 A2 CO6551670 A2 CO 6551670A2 CO 12070154 A CO12070154 A CO 12070154A CO 12070154 A CO12070154 A CO 12070154A CO 6551670 A2 CO6551670 A2 CO 6551670A2
- Authority
- CO
- Colombia
- Prior art keywords
- complex
- botulinum toxin
- botulin
- free
- purifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a los sistemas y métodos para purificar una toxina botulínica libre de complejo. En una realización, el método incluye purificar la toxina botulínica libre de complejo en estado crudo para obtener una toxina botulínica libre de complejo purificada. En esta realización, el método comprende cargar una columna de intercambio aniónico con la toxina botulinica libre de complejo en estado crudo para capturar la toxina botulínica libre de complejo en la columna de intercambio aniónico; eluir la toxina botulínica libre de complejo con un buffer para dar u eluente que incluya la toxina botulínica libre de complejo; cargar una columna de intercambio catiónico con el eluente del intercambio aniónico a la columna para permitir la captura de la toxina botulínica libre de complejo; y eluir la toxina botulínica libre de complejo con otro buffer para dar un eluente, obteniendo a partir de allí una toxina botulinica libre de complejo purificada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25381009P | 2009-10-21 | 2009-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6551670A2 true CO6551670A2 (es) | 2012-10-31 |
Family
ID=43879799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12070154A CO6551670A2 (es) | 2009-10-21 | 2012-04-30 | Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo |
Country Status (23)
Country | Link |
---|---|
US (5) | US20110092682A1 (es) |
EP (1) | EP2490986B2 (es) |
JP (1) | JP5951490B2 (es) |
KR (1) | KR101819129B1 (es) |
CN (2) | CN102666396B (es) |
AU (1) | AU2010310749B2 (es) |
BR (1) | BR112012009227A2 (es) |
CA (1) | CA2773396C (es) |
CO (1) | CO6551670A2 (es) |
CY (1) | CY1120908T1 (es) |
DK (1) | DK2490986T4 (es) |
ES (1) | ES2688065T3 (es) |
HK (2) | HK1175453A1 (es) |
HR (1) | HRP20181869T1 (es) |
HU (1) | HUE041599T2 (es) |
IL (2) | IL218532A (es) |
LT (1) | LT2490986T (es) |
MX (3) | MX2012004703A (es) |
PL (1) | PL2490986T3 (es) |
PT (1) | PT2490986T (es) |
RS (1) | RS58006B1 (es) |
SI (1) | SI2490986T1 (es) |
WO (1) | WO2011050072A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3332805T3 (da) | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
BRPI1015938A2 (pt) * | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
MX2012004703A (es) * | 2009-10-21 | 2012-06-08 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
KR102272580B1 (ko) * | 2013-07-30 | 2021-07-05 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도 |
KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
EP3901163A4 (en) * | 2018-12-21 | 2022-10-05 | The Research Foundation for Microbial Diseases of Osaka University | PROCESS FOR THE PRODUCTION OF BOTULINUM TOXIN |
KR102516204B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 정제방법 |
KR102447441B1 (ko) * | 2019-04-15 | 2022-09-27 | (주)제테마 | 보툴리눔 독소의 정제방법 |
US10851363B1 (en) * | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
KR20230009178A (ko) * | 2021-07-08 | 2023-01-17 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
KR102512757B1 (ko) * | 2021-07-22 | 2023-03-22 | (주)이니바이오 | 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US796419A (en) | 1904-07-18 | 1905-08-08 | Carl Halbig | Doll-head. |
SE303567B (es) * | 1959-02-17 | 1968-09-02 | Behringwerke Ag | |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
AU2340299A (en) * | 1998-01-26 | 1999-08-09 | University Of Massachusetts | Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
ES2617692T3 (es) * | 2000-07-21 | 2017-06-19 | Revance Therapeutics, Inc. | Sistemas de transporte de agentes biológicos de múltiples componentes |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
GB2386246B (en) | 2001-11-01 | 2005-06-29 | Marconi Applied Techn Ltd | Electron beam tube apparatus |
ATE494367T1 (de) * | 2002-12-18 | 2011-01-15 | Hoffmann La Roche | Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität |
KR100498964B1 (ko) | 2003-03-05 | 2005-07-01 | 삼성전자주식회사 | 이동단말에서의 전자파 흡수율 제어 방법 및 장치 |
AU2003271835A1 (en) * | 2003-06-06 | 2005-01-04 | Avecia Limited | Process for the separation of proteins |
WO2006096164A1 (en) * | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
US7452697B2 (en) * | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
JP2007535911A (ja) * | 2003-12-30 | 2007-12-13 | バハラ バイオテック インターナショナル リミテッド | 組換えタンパク質の製造及び精製方法 |
KR20050074806A (ko) * | 2004-01-14 | 2005-07-19 | 팜텍(주) | 결정형 보툴리늄 독소의 제조방법 |
CA3031270A1 (en) * | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (en) * | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
JP4879978B2 (ja) * | 2005-06-17 | 2012-02-22 | メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー | 生物活性化合物を発酵生産するための装置及び方法 |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
ES2537579T3 (es) * | 2006-10-27 | 2015-06-09 | The Chemo-Sero-Therapeutic Research Institute | Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante |
CN100588706C (zh) * | 2007-04-06 | 2010-02-10 | 常州千红生化制药股份有限公司 | 纯化弹性蛋白酶的方法 |
MX2009012570A (es) * | 2007-06-01 | 2010-03-15 | Merz Pharma Gmbh & Co Kgaa | Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida. |
JP5344558B2 (ja) * | 2008-10-31 | 2013-11-20 | 国立大学法人 東京医科歯科大学 | カチオン性ナノゲルを用いる粘膜ワクチン |
DK3332805T3 (da) * | 2008-12-31 | 2022-05-16 | Revance Therapeutics Inc | Injicerbare botulinumtoksinformuleringer |
US8440204B2 (en) * | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
BRPI1015938A2 (pt) * | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
MX2012004703A (es) † | 2009-10-21 | 2012-06-08 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
US8440104B2 (en) * | 2009-10-21 | 2013-05-14 | General Electric Company | Kimzeyite garnet phosphors |
WO2013181576A2 (en) * | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods of evaluating and making biologics |
US20140120077A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
JP6955491B2 (ja) * | 2015-10-29 | 2021-10-27 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
MX2019013716A (es) * | 2017-05-18 | 2020-10-12 | Revance Therapeutics Inc | Métodos de tratamiento para la distonía cervical. |
-
2010
- 2010-10-20 MX MX2012004703A patent/MX2012004703A/es active IP Right Grant
- 2010-10-20 LT LTEP10825598.5T patent/LT2490986T/lt unknown
- 2010-10-20 AU AU2010310749A patent/AU2010310749B2/en active Active
- 2010-10-20 HU HUE10825598A patent/HUE041599T2/hu unknown
- 2010-10-20 WO PCT/US2010/053389 patent/WO2011050072A1/en active Application Filing
- 2010-10-20 MX MX2015011592A patent/MX365496B/es unknown
- 2010-10-20 US US12/908,647 patent/US20110092682A1/en not_active Abandoned
- 2010-10-20 RS RS20181330A patent/RS58006B1/sr unknown
- 2010-10-20 SI SI201031746T patent/SI2490986T1/sl unknown
- 2010-10-20 US US13/394,506 patent/US20120196349A1/en not_active Abandoned
- 2010-10-20 CA CA2773396A patent/CA2773396C/en active Active
- 2010-10-20 CN CN201080045567.0A patent/CN102666396B/zh active Active
- 2010-10-20 KR KR1020127012224A patent/KR101819129B1/ko active IP Right Grant
- 2010-10-20 ES ES10825598.5T patent/ES2688065T3/es active Active
- 2010-10-20 DK DK10825598.5T patent/DK2490986T4/da active
- 2010-10-20 BR BR112012009227A patent/BR112012009227A2/pt not_active IP Right Cessation
- 2010-10-20 JP JP2012535338A patent/JP5951490B2/ja active Active
- 2010-10-20 EP EP10825598.5A patent/EP2490986B2/en active Active
- 2010-10-20 CN CN201510173705.8A patent/CN104961812B/zh active Active
- 2010-10-20 PL PL10825598T patent/PL2490986T3/pl unknown
- 2010-10-20 PT PT10825598T patent/PT2490986T/pt unknown
-
2012
- 2012-03-07 IL IL218532A patent/IL218532A/en active IP Right Grant
- 2012-04-20 MX MX2019006519A patent/MX2019006519A/es unknown
- 2012-04-30 CO CO12070154A patent/CO6551670A2/es not_active Application Discontinuation
-
2013
- 2013-02-27 HK HK13102459.5A patent/HK1175453A1/xx unknown
-
2015
- 2015-07-10 US US14/796,235 patent/US9469849B2/en active Active
-
2016
- 2016-04-05 HK HK16103844.4A patent/HK1215951A1/zh unknown
- 2016-10-17 US US15/295,134 patent/US20170029795A1/en not_active Abandoned
- 2016-10-25 IL IL248486A patent/IL248486A0/en unknown
-
2018
- 2018-09-25 CY CY181100988T patent/CY1120908T1/el unknown
- 2018-11-08 HR HRP20181869TT patent/HRP20181869T1/hr unknown
-
2019
- 2019-12-02 US US16/700,728 patent/US11466262B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6551670A2 (es) | Métodos y sistemas para purificar la neurotoxina botulínica libre de complejo | |
SG11201706545VA (en) | Systems, devices, and methods for eyebox expansion in wearable heads-up displays | |
BR112013000623A2 (pt) | purificação de proteína. | |
MX2018007134A (es) | Metodo y dispositivo de ayuda al estacionamiento. | |
BR112013032215A2 (pt) | método e sistema para processamento de consultas de saldo de contas financeiras | |
BR112015031196A2 (pt) | “processo de purificação de anticorpo monoclonal” | |
GB2488298A (en) | System and method for facilitating affiliate marketing relationships | |
BR112013002334A2 (pt) | método para purificar polipeptídeos ou imunoconjugados ativos. | |
BR112014007935A8 (pt) | Sistema para criar um relatório em uma planilha e métodos para identificar relações entre tabelas em uma planilha | |
CL2014001984A1 (es) | Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos. | |
AR069097A1 (es) | Purificacion de anticuerpos por cromatografia de intercambio cationico | |
AR076137A1 (es) | Modulo, sistema y metodo de interfaz. | |
BR112013018294A2 (pt) | sistema e método para suportar jit em um sistema seguro com faixas de memórias alocadas randomicamente | |
AR090319A1 (es) | Biorrefineria integrada | |
GB201214701D0 (en) | Method and device for labeling touch region of a display device | |
WO2013147955A3 (en) | Method and system to provide a scroll map | |
EP3076170A4 (en) | Solid-phase carrier, production method for solid-phase carrier, carrier for affinity refining, production method for filler for affinity chromatography, filler for affinity chromatography, chromatography column, and refining method | |
BR112018000464A2 (pt) | sistema de armazenamento gasoso, métodos para produzir e utilizá-lo | |
CO2019003427A2 (es) | Métodos para mejorar el resabio de bebidas alcohólicas usando alulosa | |
AR094756A1 (es) | Método para reducir el consumo de energía por acoplamiento térmico | |
BR112019001494A2 (pt) | método implementado por computador e sistema para determinar um desenho melhorado para uma lente de óculos progessiva, método para fabricação de uma lente progressiva e programa de computador não transitório | |
EA201400273A1 (ru) | Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин | |
BR112013000258B8 (pt) | Processo para preparação de uma estrutura laminada | |
AR087103A1 (es) | Tecnologia de simulacion integrada | |
TW201614621A (en) | Defect detecting method and display panel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |